{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:36:49Z","timestamp":1794875809915,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["GM131729"],"award-info":[{"award-number":["GM131729"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["GT12053"],"award-info":[{"award-number":["GT12053"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HATFUL19GO"],"award-info":[{"award-number":["HATFUL19GO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Mycobacterium chelonae<\/jats:italic>\n                    is a rare cause of chronic disseminated cutaneous infections in immunocompromised patients. Multidrug-resistant\n                    <jats:italic>M. chelonae<\/jats:italic>\n                    infections present a challenge for treatment, and prolonged antimicrobial courses lead to significant toxicities and further antimicrobial resistance. We report a case of refractory cutaneous disseminated\n                    <jats:italic>M. chelonae<\/jats:italic>\n                    infection in a patient with seronegative arthritis on immunotherapy with tofacitinib that was treated with combination antimicrobial, surgical, and single bacteriophage therapy with excellent clinical response. The patient developed neutralizing antibodies against the bacteriophage but continues to have stable improvement of disease with negative biopsies and no evidence of bacterial resistance to the phage.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-29689-4","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:04:31Z","timestamp":1651579471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-5647","authenticated-orcid":false,"given":"Jessica S.","family":"Little","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-711X","authenticated-orcid":false,"given":"Rebekah M.","family":"Dedrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-5076","authenticated-orcid":false,"given":"Krista G.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Cristinziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailey E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance A.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulip A.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6705-6821","authenticated-orcid":false,"given":"Graham F.","family":"Hatfull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"29689_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/infdis\/166.2.405","volume":"166","author":"RJ Wallace","year":"1992","unstructured":"Wallace, R. J., Brown, B. A. & Onyi, G. O. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J. Infect. Dis. 166, 405\u2013412 (1992).","journal-title":"J. Infect. Dis."},{"key":"29689_CR2","doi-asserted-by":"publisher","first-page":"ofy168","DOI":"10.1093\/ofid\/ofy168","volume":"5","author":"KM Dousa","year":"2018","unstructured":"Dousa, K. M. et al. Ibrutinib therapy and Mycobacterium chelonae skin and soft tissue infection. Open Forum Infect. Dis. 5, ofy168 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"29689_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/clinids\/5.4.657","volume":"5","author":"RJ Wallace","year":"1983","unstructured":"Wallace, R. J. et al. Spectrum of disease due to rapidly growing mycobacteria. Rev. Infect. Dis. 5, 657\u2013679 (1983).","journal-title":"Rev. Infect. Dis."},{"key":"29689_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/archderm.142.10.1287","volume":"142","author":"DZ Uslan","year":"2006","unstructured":"Uslan, D. Z., Kowalski, T. J., Wengenack, N. L., Virk, A. & Wilson, J. W. Skin and soft tissue infections due to rapidly growing mycobacteria: Comparison of clinical features, treatment, and susceptibility. Arch. Dermatol. 142, 1287\u20131292 (2006).","journal-title":"Arch. Dermatol."},{"key":"29689_CR5","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1056\/NEJMoa1205114","volume":"367","author":"BS Kennedy","year":"2012","unstructured":"Kennedy, B. S. et al. Outbreak of Mycobacterium chelonae infection associated with tattoo ink. N. Engl. J. Med 367, 1020\u20131024 (2012).","journal-title":"N. Engl. J. Med"},{"key":"29689_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJM198707233170403","volume":"317","author":"TJ Safranek","year":"1987","unstructured":"Safranek, T. J. et al. Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution. N. Engl. J. Med. 317, 197\u2013201 (1987).","journal-title":"N. Engl. J. Med."},{"key":"29689_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jhin.2021.04.028","volume":"114","author":"T Inkster","year":"2021","unstructured":"Inkster, T., Peters, C., Seagar, A. L., Holden, M. T. G. & Laurenson, I. F. Investigation of two cases of Mycobacterium chelonae infection in haemato-oncology patients using whole-genome sequencing and a potential link to the hospital water supply. J. Hosp. Infect. 114, 111\u2013116 (2021).","journal-title":"J. Hosp. Infect."},{"key":"29689_CR8","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1086\/340399","volume":"34","author":"H Meyers","year":"2002","unstructured":"Meyers, H. et al. An outbreak of Mycobacterium chelonae infection following liposuction. Clin. Infect. Dis. 34, 1500\u20131507 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"29689_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0002-9343(89)90264-7","volume":"86","author":"JF Cooper","year":"1989","unstructured":"Cooper, J. F., Lichtenstein, M. J., Graham, B. S. & Schaffner, W. Mycobacterium chelonae: a cause of nodular skin lesions with a proclivity for renal transplant recipients. Am. J. Med. 86, 173\u2013177 (1989).","journal-title":"Am. J. Med."},{"key":"29689_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1086\/322523","volume":"33","author":"BA Brown-Elliott","year":"2001","unstructured":"Brown-Elliott, B. A., Wallace, R. J., Blinkhorn, R., Crist, C. J. & Mann, L. B. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin. Infect. Dis. 33, 1433\u20131434 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"29689_CR11","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1128\/AAC.40.7.1676","volume":"40","author":"RJ Wallace","year":"1996","unstructured":"Wallace, R. J. et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. 40, 1676\u20131681 (1996).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29689_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/clinids\/20.2.443","volume":"20","author":"P Tebas","year":"1995","unstructured":"Tebas, P., Sultan, F., Wallace, R. J. & Fraser, V. Rapid development of resistance to clarithromycin following monotherapy for disseminated mycobacterium chelonae infection in a heart transplant patient. Clin. Infect. Dis. 20, 443\u2013444 (1995).","journal-title":"Clin. Infect. Dis."},{"key":"29689_CR13","first-page":"e03431","volume":"12","author":"RM Dedrick","year":"2021","unstructured":"Dedrick, R. M. et al. Mycobacterium abscessus strain morphotype determines phage susceptibility, the repertoire of therapeutically useful phages, and phage resistance. MBio 12, e03431\u201320 (2021).","journal-title":"MBio"},{"key":"29689_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730\u2013733 (2019).","journal-title":"Nat. Med."},{"key":"29689_CR15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","volume":"27","author":"RM Dedrick","year":"2021","unstructured":"Dedrick, R. M. et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat. Med. 27, 1357\u20131361 (2021).","journal-title":"Nat. Med."},{"key":"29689_CR16","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/microorganisms9112366","volume":"9","author":"CG Shield","year":"2021","unstructured":"Shield, C. G. et al. Application of bacteriophages for mycobacterial infections, from diagnosis to treatment. Microorganisms 9, 2366 (2021).","journal-title":"Microorganisms"},{"key":"29689_CR17","doi-asserted-by":"publisher","first-page":"e00066","DOI":"10.1128\/CMR.00066-18","volume":"32","author":"FL Gordillo Altamirano","year":"2019","unstructured":"Gordillo Altamirano, F. L. & Barr, J. J. Phage therapy in the postantibiotic era. Clin. Microbiol. Rev. 32, e00066\u201318 (2019).","journal-title":"Clin. Microbiol. Rev."},{"key":"29689_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijantimicag.2018.09.004","volume":"53","author":"A Kakasis","year":"2019","unstructured":"Kakasis, A. & Panitsa, G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int. J. Antimicrob. Agents 53, 16\u201321 (2019).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"29689_CR19","doi-asserted-by":"publisher","first-page":"e00954","DOI":"10.1128\/AAC.00954-17","volume":"61","author":"RT Schooley","year":"2017","unstructured":"Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, e00954\u201317 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29689_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","volume":"47","author":"N Law","year":"2019","unstructured":"Law, N. et al. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection 47, 665\u2013668 (2019).","journal-title":"Infection"},{"key":"29689_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrmicro2315","volume":"8","author":"SJ Labrie","year":"2010","unstructured":"Labrie, S. J., Samson, J. E. & Moineau, S. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 8, 317\u2013327 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"29689_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/vim.2013.0128","volume":"27","author":"M \u0141usiak-Szelachowska","year":"2014","unstructured":"\u0141usiak-Szelachowska, M. et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 295 (2014).","journal-title":"Viral Immunol."},{"key":"29689_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-med-080219-122208","volume":"73","author":"GF Hatfull","year":"2022","unstructured":"Hatfull, G. F., Dedrick, R. M. & Schooley, R. T. Phage therapy for antibiotic-resistant bacterial infections. Annu. Rev. Med. 73, 197\u2013211 (2022).","journal-title":"Annu. Rev. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29689-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29689-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29689-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:00:59Z","timestamp":1669291259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29689-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["29689"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-29689-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742121706.793593155","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"22 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A.B. receives contract and grant funding from Gilead. G.F.H. acts as consultant and grant recipient for Janssen pharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2313"}}